Skip to main navigation

Home
Products
Workflows
- Research applications
- Clinical applications
Innovation
- SOLA Technology
About
- Leadership
- Careers
- Press + news
- Distributors
- Events
- Legal
- Blog
Investors
Order
Contact

Order
Support

Investor Relations

Investors
News + events
Stock information
Corporate governance
Financials + filings
IR resources

Quarterly Results

Financials and Filings Menu

Financials and Filings Menu

SEC Filings
|
Annual report + proxy
|
Quarterly Results

Show all

2022

Q3

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
Q3 2022 Codex DNA Inc, Earnings Conference Call
Form 10-Q

Q2

Codex DNA Reports Second Quarter 2022 Financial Results
Q2 2022 Codex DNA Inc, Earnings Conference Call
Form 10-Q

Q1

Codex DNA Reports First Quarter 2022 Financial Results
Q1 2022 Codex DNA Inc, Earnings Conference Call
Form 10-Q

2021

Q4

Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance
Q4 2021 Codex DNA Inc, Earnings Conference Call
Form 10-K

Q3

Codex DNA Reports Third Quarter 2021 Financial Results
Q3 2021 Codex DNA Inc, Earnings Conference Call
Form 10-Q

Q2

Codex DNA Reports Second Quarter 2021 Financial Results
Q2 2021 Codex DNA Inc, Earnings Conference Call
Form 10-Q

About Telesis Bio

Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA.

Telesis Bio Inc. is accelerating advances in the fields of personalized medicine, biologics drug discovery, vaccine development, genome editing, and cell and gene therapy.

Site

Products
Workflows
Support
About
Investors
Order
Contact

Links

Events
Blog
Careers
Terms of use
Cookie policy
Privacy policy
Legal

© 2023 Telesis Bio Inc. All rights reserved.